aluates Reports

$ 0.0

Automative

Global FXa Inhibitor Market Research Report 2025

Published Date: March 2025

Report Code: QYRE-Auto-4H19308

BUY CHAPTERS

Global FXa Inhibitor Market Research Report 2025

Code: QYRE-Auto-4H19308

Report

March 2025

Pages:90

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Bristol–Myers Squibb

Pfizer Inc

Bayer

Daiichi Sankyo

Johnson & Johnson

Chia Tai-Tianqing Pharmaceutical

Jiangsu Jiayi Pharmaceutical

Changzhou Hengbang Pharmaceutical

Jiangxi Kerui Pharmaceutical Co., Ltd.

Qilu Pharmaceutical

Nanjing Haichen Pharmaceutical

Suzhou No.3 Pharmaceutical

Shenzhen Salubris Pharmaceuticals

Huahai Pharmaceutical

Shandong New Era Pharmaceutical

FXa Inhibitor Market Size

The global market for FXa Inhibitor was valued at US$ 34150 million in the year 2024 and is projected to reach a revised size of US$ 51470 million by 2031, growing at a CAGR of 6.2% during the forecast period.

FXa Inhibitor Market

FXa Inhibitors are a type of anticoagulant that work by selectively and reversibly blocking the activity of clotting factor Xa, preventing clot formation. They affect both factor Xa within the blood and within a preexisting clot. They do not affect platelet aggregation. They are used for the treatment and prevention of deep vein thrombosis and acute pulmonary embolism, and to reduce the risk of stroke and embolism in people with nonvalvular atrial fibrillation.

North American market for FXa Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for FXa Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for FXa Inhibitor in Hospital Pharmacy is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of FXa Inhibitor include Bristol Myers Squibb, Pfizer, Bayer, Daiichi Sankyo, Johnson & Johnson, Chia Tai-Tianqing Pharmaceutical, Jiangsu Jiayi Pharmaceutical, Changzhou Hengbang Pharmaceutical, Jiangxi Kerui Pharmaceutical Co., Ltd, Qilu Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for FXa Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding FXa Inhibitor.

The FXa Inhibitor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global FXa Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the FXa Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of FXa Inhibitor Market Report

Report Metric	Details
Report Name	FXa Inhibitor Market
Accounted market size in year	US$ 34150 million
Forecasted market size in 2031	US$ 51470 million
CAGR	6.2%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Rivaroxaban Apixaban Edoxaban Others
Segment by Application	Hospital Pharmacy Retail Pharmacy
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bristol Myers Squibb, Pfizer, Bayer, Daiichi Sankyo, Johnson & Johnson, Chia Tai-Tianqing Pharmaceutical, Jiangsu Jiayi Pharmaceutical, Changzhou Hengbang Pharmaceutical, Jiangxi Kerui Pharmaceutical Co., Ltd, Qilu Pharmaceutical, Nanjing Haichen Pharmaceutical, Suzhou No.3 Pharmaceutical, Shenzhen Salubris Pharmaceuticals, Huahai Pharmaceutical, Shandong New Era Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of FXa Inhibitor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is FXa Inhibitor Market growing?

Ans: The FXa Inhibitor Market witnessing a CAGR of 6.2% during the forecast period 2025-2031.

What is the FXa Inhibitor Market size in 2031?

Ans: The FXa Inhibitor Market size in 2031 will be US$ 51470 million.

Who are the main players in the FXa Inhibitor Market report?

Ans: The main players in the FXa Inhibitor Market are Bristol Myers Squibb, Pfizer, Bayer, Daiichi Sankyo, Johnson & Johnson, Chia Tai-Tianqing Pharmaceutical, Jiangsu Jiayi Pharmaceutical, Changzhou Hengbang Pharmaceutical, Jiangxi Kerui Pharmaceutical Co., Ltd, Qilu Pharmaceutical, Nanjing Haichen Pharmaceutical, Suzhou No.3 Pharmaceutical, Shenzhen Salubris Pharmaceuticals, Huahai Pharmaceutical, Shandong New Era Pharmaceutical

What are the Application segmentation covered in the FXa Inhibitor Market report?

Ans: The Applications covered in the FXa Inhibitor Market report are Hospital Pharmacy, Retail Pharmacy

What are the Type segmentation covered in the FXa Inhibitor Market report?

Ans: The Types covered in the FXa Inhibitor Market report are Rivaroxaban, Apixaban, Edoxaban, Others

Recommended Reports

Anticoagulant Therapies

Inhibitor Drug Markets

Blood Clot Management

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global FXa Inhibitor Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Rivaroxaban

1.2.3 Apixaban

1.2.4 Edoxaban

1.2.5 Others

1.3 Market by Application

1.3.1 Global FXa Inhibitor Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global FXa Inhibitor Market Perspective (2020-2031)

2.2 Global FXa Inhibitor Growth Trends by Region

2.2.1 Global FXa Inhibitor Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 FXa Inhibitor Historic Market Size by Region (2020-2025)

2.2.3 FXa Inhibitor Forecasted Market Size by Region (2026-2031)

2.3 FXa Inhibitor Market Dynamics

2.3.1 FXa Inhibitor Industry Trends

2.3.2 FXa Inhibitor Market Drivers

2.3.3 FXa Inhibitor Market Challenges

2.3.4 FXa Inhibitor Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top FXa Inhibitor Players by Revenue

3.1.1 Global Top FXa Inhibitor Players by Revenue (2020-2025)

3.1.2 Global FXa Inhibitor Revenue Market Share by Players (2020-2025)

3.2 Global Top FXa Inhibitor Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by FXa Inhibitor Revenue

3.4 Global FXa Inhibitor Market Concentration Ratio

3.4.1 Global FXa Inhibitor Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by FXa Inhibitor Revenue in 2024

3.5 Global Key Players of FXa Inhibitor Head office and Area Served

3.6 Global Key Players of FXa Inhibitor, Product and Application

3.7 Global Key Players of FXa Inhibitor, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 FXa Inhibitor Breakdown Data by Type

4.1 Global FXa Inhibitor Historic Market Size by Type (2020-2025)

4.2 Global FXa Inhibitor Forecasted Market Size by Type (2026-2031)

5 FXa Inhibitor Breakdown Data by Application

5.1 Global FXa Inhibitor Historic Market Size by Application (2020-2025)

5.2 Global FXa Inhibitor Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America FXa Inhibitor Market Size (2020-2031)

6.2 North America FXa Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America FXa Inhibitor Market Size by Country (2020-2025)

6.4 North America FXa Inhibitor Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe FXa Inhibitor Market Size (2020-2031)

7.2 Europe FXa Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe FXa Inhibitor Market Size by Country (2020-2025)

7.4 Europe FXa Inhibitor Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific FXa Inhibitor Market Size (2020-2031)

8.2 Asia-Pacific FXa Inhibitor Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific FXa Inhibitor Market Size by Region (2020-2025)

8.4 Asia-Pacific FXa Inhibitor Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America FXa Inhibitor Market Size (2020-2031)

9.2 Latin America FXa Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America FXa Inhibitor Market Size by Country (2020-2025)

9.4 Latin America FXa Inhibitor Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa FXa Inhibitor Market Size (2020-2031)

10.2 Middle East & Africa FXa Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa FXa Inhibitor Market Size by Country (2020-2025)

10.4 Middle East & Africa FXa Inhibitor Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bristol Myers Squibb

11.1.1 Bristol Myers Squibb Company Details

11.1.2 Bristol Myers Squibb Business Overview

11.1.3 Bristol Myers Squibb FXa Inhibitor Introduction

11.1.4 Bristol Myers Squibb Revenue in FXa Inhibitor Business (2020-2025)

11.1.5 Bristol Myers Squibb Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Details

11.2.2 Pfizer Business Overview

11.2.3 Pfizer FXa Inhibitor Introduction

11.2.4 Pfizer Revenue in FXa Inhibitor Business (2020-2025)

11.2.5 Pfizer Recent Development

11.3 Bayer

11.3.1 Bayer Company Details

11.3.2 Bayer Business Overview

11.3.3 Bayer FXa Inhibitor Introduction

11.3.4 Bayer Revenue in FXa Inhibitor Business (2020-2025)

11.3.5 Bayer Recent Development

11.4 Daiichi Sankyo

11.4.1 Daiichi Sankyo Company Details

11.4.2 Daiichi Sankyo Business Overview

11.4.3 Daiichi Sankyo FXa Inhibitor Introduction

11.4.4 Daiichi Sankyo Revenue in FXa Inhibitor Business (2020-2025)

11.4.5 Daiichi Sankyo Recent Development

11.5 Johnson & Johnson

11.5.1 Johnson & Johnson Company Details

11.5.2 Johnson & Johnson Business Overview

11.5.3 Johnson & Johnson FXa Inhibitor Introduction

11.5.4 Johnson & Johnson Revenue in FXa Inhibitor Business (2020-2025)

11.5.5 Johnson & Johnson Recent Development

11.6 Chia Tai-Tianqing Pharmaceutical

11.6.1 Chia Tai-Tianqing Pharmaceutical Company Details

11.6.2 Chia Tai-Tianqing Pharmaceutical Business Overview

11.6.3 Chia Tai-Tianqing Pharmaceutical FXa Inhibitor Introduction

11.6.4 Chia Tai-Tianqing Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025)

11.6.5 Chia Tai-Tianqing Pharmaceutical Recent Development

11.7 Jiangsu Jiayi Pharmaceutical

11.7.1 Jiangsu Jiayi Pharmaceutical Company Details

11.7.2 Jiangsu Jiayi Pharmaceutical Business Overview

11.7.3 Jiangsu Jiayi Pharmaceutical FXa Inhibitor Introduction

11.7.4 Jiangsu Jiayi Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025)

11.7.5 Jiangsu Jiayi Pharmaceutical Recent Development

11.8 Changzhou Hengbang Pharmaceutical

11.8.1 Changzhou Hengbang Pharmaceutical Company Details

11.8.2 Changzhou Hengbang Pharmaceutical Business Overview

11.8.3 Changzhou Hengbang Pharmaceutical FXa Inhibitor Introduction

11.8.4 Changzhou Hengbang Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025)

11.8.5 Changzhou Hengbang Pharmaceutical Recent Development

11.9 Jiangxi Kerui Pharmaceutical Co., Ltd

11.9.1 Jiangxi Kerui Pharmaceutical Co., Ltd Company Details

11.9.2 Jiangxi Kerui Pharmaceutical Co., Ltd Business Overview

11.9.3 Jiangxi Kerui Pharmaceutical Co., Ltd FXa Inhibitor Introduction

11.9.4 Jiangxi Kerui Pharmaceutical Co., Ltd Revenue in FXa Inhibitor Business (2020-2025)

11.9.5 Jiangxi Kerui Pharmaceutical Co., Ltd Recent Development

11.10 Qilu Pharmaceutical

11.10.1 Qilu Pharmaceutical Company Details

11.10.2 Qilu Pharmaceutical Business Overview

11.10.3 Qilu Pharmaceutical FXa Inhibitor Introduction

11.10.4 Qilu Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025)

11.10.5 Qilu Pharmaceutical Recent Development

11.11 Nanjing Haichen Pharmaceutical

11.11.1 Nanjing Haichen Pharmaceutical Company Details

11.11.2 Nanjing Haichen Pharmaceutical Business Overview

11.11.3 Nanjing Haichen Pharmaceutical FXa Inhibitor Introduction

11.11.4 Nanjing Haichen Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025)

11.11.5 Nanjing Haichen Pharmaceutical Recent Development

11.12 Suzhou No.3 Pharmaceutical

11.12.1 Suzhou No.3 Pharmaceutical Company Details

11.12.2 Suzhou No.3 Pharmaceutical Business Overview

11.12.3 Suzhou No.3 Pharmaceutical FXa Inhibitor Introduction

11.12.4 Suzhou No.3 Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025)

11.12.5 Suzhou No.3 Pharmaceutical Recent Development

11.13 Shenzhen Salubris Pharmaceuticals

11.13.1 Shenzhen Salubris Pharmaceuticals Company Details

11.13.2 Shenzhen Salubris Pharmaceuticals Business Overview

11.13.3 Shenzhen Salubris Pharmaceuticals FXa Inhibitor Introduction

11.13.4 Shenzhen Salubris Pharmaceuticals Revenue in FXa Inhibitor Business (2020-2025)

11.13.5 Shenzhen Salubris Pharmaceuticals Recent Development

11.14 Huahai Pharmaceutical

11.14.1 Huahai Pharmaceutical Company Details

11.14.2 Huahai Pharmaceutical Business Overview

11.14.3 Huahai Pharmaceutical FXa Inhibitor Introduction

11.14.4 Huahai Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025)

11.14.5 Huahai Pharmaceutical Recent Development

11.15 Shandong New Era Pharmaceutical

11.15.1 Shandong New Era Pharmaceutical Company Details

11.15.2 Shandong New Era Pharmaceutical Business Overview

11.15.3 Shandong New Era Pharmaceutical FXa Inhibitor Introduction

11.15.4 Shandong New Era Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025)

11.15.5 Shandong New Era Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Bristol–Myers Squibb

Pfizer Inc

Bayer

Daiichi Sankyo

Johnson & Johnson

Chia Tai-Tianqing Pharmaceutical

Jiangsu Jiayi Pharmaceutical

Changzhou Hengbang Pharmaceutical

Jiangxi Kerui Pharmaceutical Co., Ltd.

Qilu Pharmaceutical

Nanjing Haichen Pharmaceutical

Suzhou No.3 Pharmaceutical

Shenzhen Salubris Pharmaceuticals

Huahai Pharmaceutical

Shandong New Era Pharmaceutical

List of Tables

Table 1. Global FXa Inhibitor Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Rivaroxaban

Table 3. Key Players of Apixaban

Table 4. Key Players of Edoxaban

Table 5. Key Players of Others

Table 6. Global FXa Inhibitor Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global FXa Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global FXa Inhibitor Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global FXa Inhibitor Market Share by Region (2020-2025)

Table 10. Global FXa Inhibitor Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global FXa Inhibitor Market Share by Region (2026-2031)

Table 12. FXa Inhibitor Market Trends

Table 13. FXa Inhibitor Market Drivers

Table 14. FXa Inhibitor Market Challenges

Table 15. FXa Inhibitor Market Restraints

Table 16. Global FXa Inhibitor Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global FXa Inhibitor Market Share by Players (2020-2025)

Table 18. Global Top FXa Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in FXa Inhibitor as of 2024)

Table 19. Ranking of Global Top FXa Inhibitor Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by FXa Inhibitor Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of FXa Inhibitor, Headquarters and Area Served

Table 22. Global Key Players of FXa Inhibitor, Product and Application

Table 23. Global Key Players of FXa Inhibitor, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global FXa Inhibitor Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global FXa Inhibitor Revenue Market Share by Type (2020-2025)

Table 27. Global FXa Inhibitor Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global FXa Inhibitor Revenue Market Share by Type (2026-2031)

Table 29. Global FXa Inhibitor Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global FXa Inhibitor Revenue Market Share by Application (2020-2025)

Table 31. Global FXa Inhibitor Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global FXa Inhibitor Revenue Market Share by Application (2026-2031)

Table 33. North America FXa Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America FXa Inhibitor Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America FXa Inhibitor Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe FXa Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe FXa Inhibitor Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe FXa Inhibitor Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific FXa Inhibitor Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific FXa Inhibitor Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific FXa Inhibitor Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America FXa Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America FXa Inhibitor Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America FXa Inhibitor Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa FXa Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa FXa Inhibitor Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa FXa Inhibitor Market Size by Country (2026-2031) & (US$ Million)

Table 48. Bristol Myers Squibb Company Details

Table 49. Bristol Myers Squibb Business Overview

Table 50. Bristol Myers Squibb FXa Inhibitor Product

Table 51. Bristol Myers Squibb Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 52. Bristol Myers Squibb Recent Development

Table 53. Pfizer Company Details

Table 54. Pfizer Business Overview

Table 55. Pfizer FXa Inhibitor Product

Table 56. Pfizer Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 57. Pfizer Recent Development

Table 58. Bayer Company Details

Table 59. Bayer Business Overview

Table 60. Bayer FXa Inhibitor Product

Table 61. Bayer Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 62. Bayer Recent Development

Table 63. Daiichi Sankyo Company Details

Table 64. Daiichi Sankyo Business Overview

Table 65. Daiichi Sankyo FXa Inhibitor Product

Table 66. Daiichi Sankyo Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 67. Daiichi Sankyo Recent Development

Table 68. Johnson & Johnson Company Details

Table 69. Johnson & Johnson Business Overview

Table 70. Johnson & Johnson FXa Inhibitor Product

Table 71. Johnson & Johnson Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 72. Johnson & Johnson Recent Development

Table 73. Chia Tai-Tianqing Pharmaceutical Company Details

Table 74. Chia Tai-Tianqing Pharmaceutical Business Overview

Table 75. Chia Tai-Tianqing Pharmaceutical FXa Inhibitor Product

Table 76. Chia Tai-Tianqing Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 77. Chia Tai-Tianqing Pharmaceutical Recent Development

Table 78. Jiangsu Jiayi Pharmaceutical Company Details

Table 79. Jiangsu Jiayi Pharmaceutical Business Overview

Table 80. Jiangsu Jiayi Pharmaceutical FXa Inhibitor Product

Table 81. Jiangsu Jiayi Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 82. Jiangsu Jiayi Pharmaceutical Recent Development

Table 83. Changzhou Hengbang Pharmaceutical Company Details

Table 84. Changzhou Hengbang Pharmaceutical Business Overview

Table 85. Changzhou Hengbang Pharmaceutical FXa Inhibitor Product

Table 86. Changzhou Hengbang Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 87. Changzhou Hengbang Pharmaceutical Recent Development

Table 88. Jiangxi Kerui Pharmaceutical Co., Ltd Company Details

Table 89. Jiangxi Kerui Pharmaceutical Co., Ltd Business Overview

Table 90. Jiangxi Kerui Pharmaceutical Co., Ltd FXa Inhibitor Product

Table 91. Jiangxi Kerui Pharmaceutical Co., Ltd Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 92. Jiangxi Kerui Pharmaceutical Co., Ltd Recent Development

Table 93. Qilu Pharmaceutical Company Details

Table 94. Qilu Pharmaceutical Business Overview

Table 95. Qilu Pharmaceutical FXa Inhibitor Product

Table 96. Qilu Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 97. Qilu Pharmaceutical Recent Development

Table 98. Nanjing Haichen Pharmaceutical Company Details

Table 99. Nanjing Haichen Pharmaceutical Business Overview

Table 100. Nanjing Haichen Pharmaceutical FXa Inhibitor Product

Table 101. Nanjing Haichen Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 102. Nanjing Haichen Pharmaceutical Recent Development

Table 103. Suzhou No.3 Pharmaceutical Company Details

Table 104. Suzhou No.3 Pharmaceutical Business Overview

Table 105. Suzhou No.3 Pharmaceutical FXa Inhibitor Product

Table 106. Suzhou No.3 Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 107. Suzhou No.3 Pharmaceutical Recent Development

Table 108. Shenzhen Salubris Pharmaceuticals Company Details

Table 109. Shenzhen Salubris Pharmaceuticals Business Overview

Table 110. Shenzhen Salubris Pharmaceuticals FXa Inhibitor Product

Table 111. Shenzhen Salubris Pharmaceuticals Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 112. Shenzhen Salubris Pharmaceuticals Recent Development

Table 113. Huahai Pharmaceutical Company Details

Table 114. Huahai Pharmaceutical Business Overview

Table 115. Huahai Pharmaceutical FXa Inhibitor Product

Table 116. Huahai Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 117. Huahai Pharmaceutical Recent Development

Table 118. Shandong New Era Pharmaceutical Company Details

Table 119. Shandong New Era Pharmaceutical Business Overview

Table 120. Shandong New Era Pharmaceutical FXa Inhibitor Product

Table 121. Shandong New Era Pharmaceutical Revenue in FXa Inhibitor Business (2020-2025) & (US$ Million)

Table 122. Shandong New Era Pharmaceutical Recent Development

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. FXa Inhibitor Picture

Figure 2. Global FXa Inhibitor Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global FXa Inhibitor Market Share by Type: 2024 VS 2031

Figure 4. Rivaroxaban Features

Figure 5. Apixaban Features

Figure 6. Edoxaban Features

Figure 7. Others Features

Figure 8. Global FXa Inhibitor Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global FXa Inhibitor Market Share by Application: 2024 VS 2031

Figure 10. Hospital Pharmacy Case Studies

Figure 11. Retail Pharmacy Case Studies

Figure 12. FXa Inhibitor Report Years Considered

Figure 13. Global FXa Inhibitor Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global FXa Inhibitor Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global FXa Inhibitor Market Share by Region: 2024 VS 2031

Figure 16. Global FXa Inhibitor Market Share by Players in 2024

Figure 17. Global FXa Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 18. The Top 10 and 5 Players Market Share by FXa Inhibitor Revenue in 2024

Figure 19. North America FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America FXa Inhibitor Market Share by Country (2020-2031)

Figure 21. United States FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe FXa Inhibitor Market Share by Country (2020-2031)

Figure 25. Germany FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific FXa Inhibitor Market Share by Region (2020-2031)

Figure 33. China FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America FXa Inhibitor Market Share by Country (2020-2031)

Figure 41. Mexico FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa FXa Inhibitor Market Share by Country (2020-2031)

Figure 45. Turkey FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE FXa Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Bristol Myers Squibb Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 49. Pfizer Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 50. Bayer Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 51. Daiichi Sankyo Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 52. Johnson & Johnson Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 53. Chia Tai-Tianqing Pharmaceutical Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 54. Jiangsu Jiayi Pharmaceutical Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 55. Changzhou Hengbang Pharmaceutical Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 56. Jiangxi Kerui Pharmaceutical Co., Ltd Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 57. Qilu Pharmaceutical Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 58. Nanjing Haichen Pharmaceutical Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 59. Suzhou No.3 Pharmaceutical Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 60. Shenzhen Salubris Pharmaceuticals Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 61. Huahai Pharmaceutical Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 62. Shandong New Era Pharmaceutical Revenue Growth Rate in FXa Inhibitor Business (2020-2025)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Rivaroxaban Drugs Market Research Report 2024

Global Edoxaban Tosilate Tablets and Generic Drugs Market Research Report 2024

Global Edoxaban Reagent Market Research Report 2024

Global Direct Oral Anticoagulants DOACs Market Research Report 2024

Global Direct Thrombin Inhibitors DTIs Market Research Report 2024

Global Thrombin Inhibitor Market Research Report 2024

Global Dabigatran Etexilate Mesylate Market Research Report 2024

Global Enoxaparin Sodium Market Research Report 2024

Global Heparin Market Insights Forecast to 2030

Global Oral Factor Xa Inhibitors Market Research Report 2024

Rivaroxaban API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Antithrombin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Anticoagulant Reversal Agent Market Research Report 2024

Anti Inhibitor Coagulant Complex Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Factor Xa Market Research Report 2025

Global Heparin Sodium Market Insights Forecast to 2030

Global Edoxaban API Market Research Report 2024

Global Anticoagulant Medicines Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions